One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Table of Contents
doi : 10.1016/S0923-7534(22)04170-9
Volume 33, Issue 11, November 2022, Pages i-ii
Neoadjuvant immunotherapy in triple-negative breast cancer: lesson learnt, remaining questions
G.Bianchini1L.Licata1G.Viale1L.Gianni2
doi : 10.1016/j.annonc.2022.08.088
Volume 33, Issue 11, November 2022, Pages 1091-1093
The prognostic value of TILs in stage III colon cancer must consider sidedness
V.Moreno1234R.Salazar1235S.B.Gruber6
doi : 10.1016/j.annonc.2022.09.155
Volume 33, Issue 11, November 2022, Pages 1094-1096
ESO–ESMO fifth international consensus guidelines for breast cancer in young women (BCY5)
S.Paluch-Shimon1†F.Cardoso2†A.H.Partridge3O.Abulkhair4H.A.Azim5G.Bianchi-Micheli6M.J.Cardoso2G.Curigliano78K.A.Gelmon9O.Gentilini10N.Harbeck11B.Kaufman12S.B.Kim13Q.Liu14J.Merschdorf15P.Poortmans16G.Pruneri17E.Senkus18…O.Pagani23‡
doi : 10.1016/j.annonc.2022.07.007
Volume 33, Issue 11, November 2022, Pages 1097-1118
ESMO Expert Consensus Statements on Cancer Survivorship: promoting high-quality survivorship care and research in Europe
I.Vaz-Luis12M.Masiero34G.Cavaletti5A.Cervantes67R.T.Chlebowski8G.Curigliano39E.Felip10A.R.Ferreira1112P.A.Ganz13J.Hegarty14J.Jeon15C.Johansen16F.Joly17K.Jordan1819B.Koczwara20P.Lagergren2122M.Lambertini2324D.Lenihan25…G.Pravettoni34
doi : 10.1016/j.annonc.2022.07.1941
Volume 33, Issue 11, November 2022, Pages 1119-1133
Targeting the complexity of ERBB2 biology in gastroesophageal carcinoma
J.E.Augustin123P.Soussan45A.J.Bass16
doi : 10.1016/j.annonc.2022.08.001
Volume 33, Issue 11, November 2022, Pages 1134-1148
Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response
S.Loibl12A.Schneeweiss3J.Huober45M.Braun6J.Rey1J.-U.Blohmer7J.Furlanetto1D.-M.Zahm8C.Hanusch6J.Thomalla9C.Jackisch10P.Staib11T.Link12K.Rhiem13C.Solbach14P.A.Fasching15V.Nekljudova1C.Denkert16…M.Untch17
doi : 10.1016/j.annonc.2022.07.1940
Volume 33, Issue 11, November 2022, Pages 1149-1158
Association of tumor-infiltrating lymphocytes with survival depends on primary tumor sidedness in stage III colon cancers (NCCTG N0147) [Alliance]
B.Saberzadeh-Ardestani1N.R.Foster23H.E.Lee4Q.Shi23S.R.Alberts5T.C.Smyrk4F.A.Sinicrope156
doi : 10.1016/j.annonc.2022.07.1942
Volume 33, Issue 11, November 2022, Pages 1159-1167
Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial
F.Griesinger1G.Curigliano23M.Thomas4V.Subbiah5C.S.Baik6D.S.W.Tan7D.H.Lee8D.Misch9E.Garralda10D.-W.Kim11A.J.van der Wekken12J.F.Gainor13L.Paz-Ares14S.V.Liu15G.P.Kalemkerian16Y.Houvras17D.W.Bowles18A.S.Mansfield19…J.Mazières23
doi : 10.1016/j.annonc.2022.08.002
Volume 33, Issue 11, November 2022, Pages 1168-1178
First-line avelumab for patients with PD-L1-positive metastatic or locally advanced urothelial cancer who are unfit for cisplatin
R.Iacovelli1C.Ciccarese1M.Brunelli2N.Battelli3C.Buttigliero4C.Caserta5S.Buti67D.Santini89C.Carella10L.Galli11E.Verri12P.Ermacora13S.Merler14C.Masini15R.De Vivo16L.Milesi17F.Spina18M.Rizzo19…G.Tortora1â€
doi : 10.1016/j.annonc.2022.07.011
Volume 33, Issue 11, November 2022, Pages 1179-1185
Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancers
A.Jahn1234‡A.Rump1234‡T.J.Widmann1234‡C.Heining245P.Horak67B.Hutter89N.Paramasivam8S.Uhrig89L.Gieldon10S.Drukewitz211A.Kübler14M.Bermudez14K.Hackmann14J.Porrmann14J.Wagner14M.Arlt14M.Franke14J.Fischer14…B.Klink1234115859§
doi : 10.1016/j.annonc.2022.07.008
Volume 33, Issue 11, November 2022, Pages 1186-1199
Molecular profiling and precision medicine in rare gastrointestinal cancers within EURACAN in the SPECTA Arcagen study (EORTC-1843): too few patients with matched treatment in Europe
A.Lamarca123†M.Morfouace4†S.Tejpar5J.Oliveira6A.Capela7N.Penel8C.Gennigens9B.Brasiuniene1011J.Peron12A.Stevovic4J.-Y.Blay13‡H.-J.Klümpen1415‡
doi : 10.1016/j.annonc.2022.07.006
Volume 33, Issue 11, November 2022, Pages 1200-1202
A multicentre study of pembrolizumab time-of-day infusion patterns and clinical outcomes in non-small-cell lung cancer: too soon to promote morning infusions
A.Cortellini1A.P.C.Barrichello2J.V.Alessi2B.Ricciuti2V.R.Vaz2T.Newsom-Davis3J.S.Evans1G.Lamberti24F.Pecci2P.Viola5A.D’Alessio16C.A.M.Fulgenzi17M.M.Awad2D.J.Pinato18
doi : 10.1016/j.annonc.2022.07.1851
Volume 33, Issue 11, November 2022, Pages 1202-1204
Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay
D.J.McGrail12P.G.Pilié3N.U.Rashid45L.Voorwerk6M.Slagter789M.Kok610E.Jonasch3M.Khasraw11A.B.Heimberger12N.T.Ueno13R.Ferrarotto14J.T.Chang1516S.-Y.Lin17
doi : 10.1016/j.annonc.2022.07.009
Volume 33, Issue 11, November 2022, Pages 1204-1206
Humoral and cellular response before and after the fourth BNT162b2 vaccine dose in patients with solid tumors on active treatment
A.Lasagna1†F.Bergami2†D.Lilleri2E.Percivalle2M.Quaccini1G.Comolli2A.Sarasini2J.C.Sammartino2A.Ferrari2F.Arena2D.Cicognini1R.Schiavo3G.Lo Cascio3F.Baldanti24P.Pedrazzoli15†I.Cassaniti2â€
doi : 10.1016/j.annonc.2022.07.012
Volume 33, Issue 11, November 2022, Pages 1207-1208
